These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 25528023)

  • 1. INPP4B and RAD50 have an interactive effect on survival after breast cancer.
    Dai X; Fagerholm R; Khan S; Blomqvist C; Nevanlinna H
    Breast Cancer Res Treat; 2015 Jan; 149(2):363-71. PubMed ID: 25528023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic interactions between INPP4B and RAD50 is prognostic of breast cancer survival.
    Chen X; Theobard R; Zhang J; Dai X
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31872854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival.
    Weigman VJ; Chao HH; Shabalin AA; He X; Parker JS; Nordgard SH; Grushko T; Huo D; Nwachukwu C; Nobel A; Kristensen VN; Børresen-Dale AL; Olopade OI; Perou CM
    Breast Cancer Res Treat; 2012 Jun; 133(3):865-80. PubMed ID: 22048815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.
    Zhang M; Liu G; Xue F; Edwards R; Sood AK; Zhang W; Yang D
    Gynecol Oncol; 2016 Apr; 141(1):57-64. PubMed ID: 27016230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological and clinical significance of loss of heterozygosity at the INPP4B gene locus in Japanese breast cancer.
    Tokunaga E; Yamashita N; Kitao H; Tanaka K; Taketani K; Inoue Y; Saeki H; Oki E; Oda Y; Maehara Y
    Breast; 2016 Feb; 25():62-8. PubMed ID: 26577950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAD50 germline mutations are associated with poor survival in BRCA1/2-negative breast cancer patients.
    Fan C; Zhang J; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Int J Cancer; 2018 Oct; 143(8):1935-1942. PubMed ID: 29726012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.
    Sueta A; Yamamoto Y; Yamamoto-Ibusuki M; Hayashi M; Takeshita T; Yamamoto S; Iwase H
    PLoS One; 2014; 9(12):e116054. PubMed ID: 25542038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAD50 and NBS1 are not likely to be susceptibility genes in Chinese non-BRCA1/2 hereditary breast cancer.
    He M; Di GH; Cao AY; Hu Z; Jin W; Shen ZZ; Shao ZM
    Breast Cancer Res Treat; 2012 May; 133(1):111-6. PubMed ID: 21811815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor.
    Asleh-Aburaya K; Sheffield BS; Kos Z; Won JR; Wang XQ; Gao D; Wolber R; Gilks CB; Bernard PS; Chia SK; Nielsen TO
    Histopathology; 2017 Jan; 70(2):185-194. PubMed ID: 27402148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex.
    Hsu HM; Wang HC; Chen ST; Hsu GC; Shen CY; Yu JC
    Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2024-32. PubMed ID: 17932350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
    Engelstaedter V; Schiffers J; Kahlert S; Mainka P; Engel J; Kirchner T; Diebold J; Mayr D
    Diagn Mol Pathol; 2012 Jun; 21(2):77-83. PubMed ID: 22555090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
    Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
    Jeon YW; Kang SH; Park MH; Lim W; Cho SH; Suh YJ
    BMC Cancer; 2015 Nov; 15():865. PubMed ID: 26546331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability.
    Heikkinen K; Rapakko K; Karppinen SM; Erkko H; Knuutila S; Lundán T; Mannermaa A; Børresen-Dale AL; Borg A; Barkardottir RB; Petrini J; Winqvist R
    Carcinogenesis; 2006 Aug; 27(8):1593-9. PubMed ID: 16474176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional identification of a novel transcript variant of INPP4B in human colon and breast cancer cells.
    Croft A; Guo ST; Sherwin S; Farrelly M; Yan XG; Zhang XD; Jiang CC
    Biochem Biophys Res Commun; 2017 Mar; 485(1):47-53. PubMed ID: 28189677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status.
    Murphy NC; Biankin AV; Millar EK; McNeil CM; O'Toole SA; Segara D; Crea P; Olayioye MA; Lee CS; Fox SB; Morey AL; Christie M; Musgrove EA; Daly RJ; Lindeman GJ; Henshall SM; Visvader JE; Sutherland RL
    Int J Cancer; 2010 Mar; 126(6):1445-53. PubMed ID: 19676041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
    Aalders KC; Kuijer A; Straver ME; Slaets L; Litiere S; Viale G; Van't Veer LJ; Glas AM; Delorenzi M; van Dalen T; Tryfonidis K; Piccart MJ; Cardoso F; Rutgers EJ;
    Eur J Cancer; 2017 Jul; 79():98-105. PubMed ID: 28477490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
    Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.